/PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Genpharm announced today that NURTEC® ODT (rimegepant) was approved.
Science 37® and Xperiome™ Partner to Increase the Efficiency and Speed of Rare Disease Studies for Patients and Providers
Using Science 37 s decentralized clinical trial model, the partnership offers Xperiome s research-ready, rare disease patients more study opportunities with less burden.
News provided by
Share this article
Share this article
LOS ANGELES, March 11, 2021 /PRNewswire/ Science 37, the industry leader in decentralized clinical trials, announced today a partnership with Xperiome, a global rare disease healthtech company. The partnership further strengthens Science 37 s capabilities to bring research directly to patients, both by easing the patient burden and enabling treating physicians the opportunity to advance research as an investigator. Science 37 will leverage Xperiome s insights from Raremark, its data-driven knowledge bank powered by patients, including a specialized matching engine to connect research-ready members to clinical and real-world study op
Kibow Biotech Supports World Kidney Day 2021
News provided by
Share this article
Share this article
NEWTOWN SQUARE, Pa., March 11, 2021 /PRNewswire/ Kibow Biotech is pleased to support World Kidney Day s global campaign to raise awareness of the importance of our kidneys to overall health and to reduce the frequency and impact of kidney disease and associated health problems worldwide. Kibow will mark World Kidney Day, March 11, 2021, with a significant social media campaign to increase awareness of the importance of maintaining kidney function and remembering the kidney transplant shortage that affects patients worldwide. Throughout 23-years of continuous R&D, Kibow Biotech s dedicated staff have been privileged to provide support to people worldwide in their struggle with kidney function problems with RENADYL™ (See: www.RENADYL.com).
Atropos Health Announces Key Additions to its Founding Team to Accelerate Product Development and Customer Deployment
News provided by
Share this article
Share this article
PALO ALTO, Calif., March 11, 2021 /PRNewswire/ Today, Atropos Health, the developer of the first physician consultation service powered by research grade real-world evidence, announces four key additions to its founding team: Neil Sanghavi as President and Head of Solutions, Sharath Reddy as CFO and Head of Corporate Development, Vladimir Polony as Director of Engineering, and Yen Low as Director of Data Science.
Atropos Health RWD Bedside Service Atropos Health was launched to scale our work of bringing real-world evidence to the bedside
/PRNewswire/ In an ongoing effort to slow the spread of the virus and help communities reopen, CVS Health (NYSE: CVS) today announced that it will begin to.